Non-invasive management options for erectile dysfunction when a phosphodiesterase type 5 inhibitor fails
M Lee, R Sharifi - Drugs & aging, 2018 - Springer
Phosphodiesterase type 5 inhibitors (PDE5Is) are the drug of choice for medical
management of erectile dysfunction (ED). On-demand PDE5Is have an overall efficacy of 60 …
management of erectile dysfunction (ED). On-demand PDE5Is have an overall efficacy of 60 …
Sexual difficulties after pelvic radiotherapy: improving clinical management
ID White - Clinical Oncology, 2015 - Elsevier
Modern multimodality cancer treatment has led to more than 2 million people living with and
beyond cancer in the UK, an impressive survival statistic on which clinicians and services …
beyond cancer in the UK, an impressive survival statistic on which clinicians and services …
The 2018 revision to the process of care model for management of erectile dysfunction
JP Mulhall, A Giraldi, G Hackett… - The journal of sexual …, 2018 - academic.oup.com
Introduction Erectile dysfunction (ED) is a common condition the treatment of which over the
years has expanded from specialty care settings to various other clinical settings. A Process …
years has expanded from specialty care settings to various other clinical settings. A Process …
Combination therapy with topical alprostadil and phosphodiesterase-5 inhibitors after failure of oral therapy in patients with erectile dysfunction: a prospective, two-arm …
P Garrido-Abad, I Senra-Bravo, C Manfredi… - International journal of …, 2022 - nature.com
Phosphodiesterase type 5 inhibitors (PDE5Is) are the first-line therapeutic option for erectile
dysfunction (ED), while second-line therapy includes the alprostadil. Due to the different …
dysfunction (ED), while second-line therapy includes the alprostadil. Due to the different …
[HTML][HTML] Practical approaches to treat ED in PDE5i nonresponders
Z Cai, X Song, J Zhang, B Yang, H Li - Aging and disease, 2020 - ncbi.nlm.nih.gov
Erectile dysfunction (ED) is a common sexual disorder in adult males and one of the most
important factors affecting their quality of life and that of their partners. Although PDE5 …
important factors affecting their quality of life and that of their partners. Although PDE5 …
Clinical guidelines on erectile dysfunction surgery: EAU-AUA perspectives
Introduction The implantation of a penile prosthesis is considered a third-line treatment and
is indicated in patients who do not respond adequately to pharmacotherapy or require …
is indicated in patients who do not respond adequately to pharmacotherapy or require …
Considerations for prescribing pharmacotherapy for the treatment of erectile dysfunction
AM Bakr, AA El-Sakka, AI El-Sakka - Expert Opinion on …, 2021 - Taylor & Francis
Introduction: The effectiveness of phosphodiesterase type 5 inhibitors (PDE5i) in treating
erectile dysfunction (ED) creates a new field of both medical practice and pharmaceutical …
erectile dysfunction (ED) creates a new field of both medical practice and pharmaceutical …
Enquête sur l'utilisation de Vitaros® en pratique de médecine sexuelle et de sexologie
MH Colson, P Costa - Sexologies, 2016 - Elsevier
Résumé Introduction La présente étude a été réalisée afin d'évaluer, un an après sa mise
sur le marché, l'utilisation et la perception à la fois des patients et des médecins de Vitaros® …
sur le marché, l'utilisation et la perception à la fois des patients et des médecins de Vitaros® …
Satisfacción y adherencia al tratamiento en disfunción eréctil a medio y largo plazo
J Panach-Navarrete, A Morales-Giraldo… - Actas Urológicas …, 2017 - Elsevier
Introducción El objetivo ha sido mostrar la satisfacción y adherencia al tratamiento en
disfunción eréctil (DE) a medio y largo plazo. Material y métodos Estudio descriptivo y …
disfunción eréctil (DE) a medio y largo plazo. Material y métodos Estudio descriptivo y …
Conservative therapy of erectile dysfunction
M Trottmann, J Marcon, S Pompe, D Strobach… - Der Urologe, 2015 - Springer
Die erektile Dysfunktion (ED) ist mit einer Prävalenz von 19, 2% und einem steilen
altersabhängigen Anstieg auf 53, 4% bei den über 70-Jährigen eine häufige Sexualstörung …
altersabhängigen Anstieg auf 53, 4% bei den über 70-Jährigen eine häufige Sexualstörung …